National Cancer Centre, Tokyo, Japan

Founded as a hub for cancer treatment and research by the central government in 1962, the National Cancer Center has since lead the field. The Center was designated an Incorporated Administrative Agency in April 2010, then subsequently a National Research and Development Agency in April 2015, with a renewed commission to explore and address issues, complementing academia and the private sector. To serve as a nucleus of clinical research and development, the Hospital (Tsukiji campus) and Hospital East (Kashiwa campus) were designated as core hospitals for clinical research respectively in August and September of 2015, since then leading world class clinical research and investigator-initiated trials. It is essential to control cancer with both basic research as well as treatment, and it is our duty to form strategies and present to the nation and to the Japanese people.

Currently, one in every two Japanese citizens will develop cancer in their lifetime. Nearly one million people are newly diagnosed with cancer every year; and as the population is aging, we expect cancer patient numbers to build up. The mission of the National Cancer Center is not only to provide the best possible care including genomic medicine to each individual cancer patient, based on genomic and other clinical and biological information, but also to prevent the onset of cancer by identifying high-risk groups, developing and implementing effective prevention measures. In other words, we are to establish, practice and promote precision medicine tailored to individual patients. To achieve these objectives, it is essential to elucidate traits and diversity of cancer in individuals with integrated omics research including genomic analysis, and to develop optimal individual treatment and prevention methods. Developing an understanding of localized immune response in tumor tissue is also urgently called for.

The following has been our recent focus, in implementing the national Comprehensive 10-year Strategy for Cancer Control, in action from 2014, under the slogan “towards complete recovery from, prevention against, and dealing with cancer”:

• Reinforcing research and clinical systems to address unmet medical needs
• Developing a framework to provide optimized treatment and preemptive medical care for individual patients, based on genomic information

Following the revolutionary leap in genome sequencing technology, our nation is building the infrastructure to implement cancer genomic medicine into our national healthcare system. Our hospitals on both Tsukiji and Kashiwa campuses were designated as core hospitals for cancer genomic medicine in March 2018. It is imperative that we work with cancer genomic medicine cooperative hospitals across the nation, to ensure the delivery and quality of the new services, by sharing knowledge and nurturing specialists.

Experts at our two campuses are to integrate our insight and experience to advocate new cancer control strategies and policies. Collaboration with industrial and academic research institutions, to realize effective control over cancer is indispensable. The wishes and hopes of the Japanese citizens, including cancer patients and their families, need to be addressed, towards providing solutions. I, as President, wish to develop and reinforce a system for providing medical care that will allow all cancer patients and their families to keep their hopes alive.

Medical Oncology

Surgical Oncology

Chemotherapy

Radiation Therapy

Immunotherapy

Targeted Therapy

17 operation rooms; 5700 operations/annum
• Advanced endoscopic surgery for early gastric cancer
EMR endoscopic mucosal resection
ESD endoscopic submucosal dissection
• Cutting-edge Interventional radiology with 2 Angio-CT systems
• Hematopoietic Stem Cell Transplant
• Palliative Medication and Patient Support
• Hospital based clinical trials and research

1500 patients/day(new and returning)
• Out-patient treatment center
• (69 beds): chemotherapy for 175
patients/day
• High precision radiation therapy

High-precision screening with spiralCT, PET (positron emission tomography)
• 3,000 screenings/annum

Distance from Tokyo airport to National Cancer Centre Japan is around 19 Kms.

3 min walk from Tsukijishijo Station（Toei Oedo Subway)
5 min walk from Tsukiji Station （Tokyo Metro Hibiya Subway）
6 min walk from Higashi-ginza Station （Toei Asakusa Subway, Tokyo Metro Hibiya Subway）
9 min walk from Shintomicho Station （Tokyo Metro Yurakucho Subway）

4-minute taxi ride or 6-minute Tobu Bus ride for National Cancer Center Hospital East from West Exit of Kashiwanoha-campus Station (on the Tukuba Express line)
20-minute taxi ride or 30-minute Tobu Bus ride for National Cancer Center Hospital East from West Exit of Kashiwa Station (on the JR Joban line or Tokyo Metro Chiyoda line or Tobu Noda line)
7-minute taxi ride or 10-minute Tobu Bus ride for National Cancer Center Hopstital East from East Exit of Edogawadai station on the Tobu Noda line
40-minute ride by highway bus for Edogawadai Station from Tokyo Station Yaesu South Exit
75-minute ride by highway bus for Kashiwa Station West Exit from Haneda Tokyo International Airportt
5-minute drive from The Joban Expressway Kashiwa I.C., Turn at 500m ahead right from Chiba direction exit on Route 16

National Cancer Centre Japan

5 Chome-1-1 Tsukiji, Chuo City, Tokyo 104-0045, Japan

National Cancer Center (NCCJ) was established by the Ministry of Health and Welfare in 1962, commissioned to lead the nation’s cancer treatment, prevention, control programmes, research and education. With a workforce over 3.500, including 600 physicians and 1.200 nurses, the Center provides comprehensive clinical services to patients at its two hospitals with 1.000 beds. The 400 staff at the research institute conduct basic research. The Center also conducts research on prevention and screening, along with translational and clinical research, hosts the national cancer registry and a national database for cancer genomic medicine. The center also provides accurate and up-to-date information to the public and healthcare professionals and supports 436 cancer institutions nationwide to ensure access to equal standards of care. The leadership participates and leads expert bodies appointed by the Ministry of Health, Labour and Welfare in the fight against cancer. Expertise is shared with the medical profession globally, with a focus on Asia. In 2010, it was designated an independent administrative institute (autonomous public service body), remaining under the auspices of the Ministry of Health, Labour and Welfare. NCC has been a full member since 1968.